WO2010103278A1 - Composés bi-aromatiques destinés à être utilisés en tant qu'inhibiteurs de ltc4 synthase - Google Patents

Composés bi-aromatiques destinés à être utilisés en tant qu'inhibiteurs de ltc4 synthase Download PDF

Info

Publication number
WO2010103278A1
WO2010103278A1 PCT/GB2010/000438 GB2010000438W WO2010103278A1 WO 2010103278 A1 WO2010103278 A1 WO 2010103278A1 GB 2010000438 W GB2010000438 W GB 2010000438W WO 2010103278 A1 WO2010103278 A1 WO 2010103278A1
Authority
WO
WIPO (PCT)
Prior art keywords
aromatic compounds
synthase inhibitors
bis aromatic
ltc4 synthase
ltc4
Prior art date
Application number
PCT/GB2010/000438
Other languages
English (en)
Inventor
Peter Nilsson
Benjamin Pelcman
Martins Katkevics
Original Assignee
Biolipox Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biolipox Ab filed Critical Biolipox Ab
Priority to EP10709919A priority Critical patent/EP2406219A1/fr
Priority to JP2011553512A priority patent/JP2012520275A/ja
Priority to CA2754781A priority patent/CA2754781A1/fr
Priority to US13/256,003 priority patent/US20120004244A1/en
Priority to CN2010800110410A priority patent/CN102348686A/zh
Priority to EP10722732A priority patent/EP2406223A2/fr
Priority to US13/256,122 priority patent/US20110319431A1/en
Priority to CA2754946A priority patent/CA2754946A1/fr
Priority to PCT/GB2010/000481 priority patent/WO2010103297A2/fr
Publication of WO2010103278A1 publication Critical patent/WO2010103278A1/fr
Priority to EP11713851A priority patent/EP2545036A1/fr
Priority to PCT/GB2011/000358 priority patent/WO2011110824A1/fr
Priority to US13/634,221 priority patent/US20130035358A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)

Abstract

La présente invention concerne des composés représentés par la formule (I), dans laquelle E1, E2a, E2b, E2c, E4, D1, D2, D3, L1, Y1, L2 et Y2 ont les significations telles que données dans la description, et des sels pharmaceutiquement acceptables de ces composés. Les composés se révèlent utiles pour le traitement de maladies dans lesquelles l'inhibition de la leucotriène C4 synthase est souhaitée et/ou nécessaire, et particulièrement pour le traitement d'une affection respiratoire et/ou d'une inflammation.
PCT/GB2010/000438 2009-03-12 2010-03-12 Composés bi-aromatiques destinés à être utilisés en tant qu'inhibiteurs de ltc4 synthase WO2010103278A1 (fr)

Priority Applications (12)

Application Number Priority Date Filing Date Title
EP10709919A EP2406219A1 (fr) 2009-03-12 2010-03-12 Composés bi-aromatiques destinés à être utilisés en tant qu'inhibiteurs de ltc4 synthase
JP2011553512A JP2012520275A (ja) 2009-03-12 2010-03-12 Ｌｔｃ４シンターゼ阻害剤としての使用のためのビス芳香族化合物
CA2754781A CA2754781A1 (fr) 2009-03-12 2010-03-12 Composes bi-aromatiques destines a etre utilises en tant qu'inhibiteurs de ltc4 synthase
US13/256,003 US20120004244A1 (en) 2009-03-12 2010-03-12 Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors
CN2010800110410A CN102348686A (zh) 2009-03-12 2010-03-12 用作ltc4合酶抑制剂的双芳族化合物
EP10722732A EP2406223A2 (fr) 2009-03-12 2010-03-15 Composés bis aromatiques destinés à utilisation en tant qu'inhibiteurs de ltc4 synthase
US13/256,122 US20110319431A1 (en) 2009-03-12 2010-03-15 Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors
CA2754946A CA2754946A1 (fr) 2009-03-12 2010-03-15 Composes bis aromatiques destines a utilisation en tant qu'inhibiteurs de ltc4 synthase
PCT/GB2010/000481 WO2010103297A2 (fr) 2009-03-12 2010-03-15 Composés bis aromatiques destinés à utilisation en tant qu'inhibiteurs de ltc4 synthase
EP11713851A EP2545036A1 (fr) 2010-03-12 2011-03-14 Composés bis aromatiques destinés à être utilisés en tant qu'inhibiteurs de ltc4 synthase
PCT/GB2011/000358 WO2011110824A1 (fr) 2010-03-12 2011-03-14 Composés bis aromatiques destinés à être utilisés en tant qu'inhibiteurs de ltc4 synthase
US13/634,221 US20130035358A1 (en) 2009-03-12 2011-03-14 Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20254909P 2009-03-12 2009-03-12
US61/202,549 2009-03-12

Publications (1)

Publication Number Publication Date
WO2010103278A1 true WO2010103278A1 (fr) 2010-09-16

Family

ID=42133546

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2010/000438 WO2010103278A1 (fr) 2009-03-12 2010-03-12 Composés bi-aromatiques destinés à être utilisés en tant qu'inhibiteurs de ltc4 synthase

Country Status (8)

Country Link
US (2) US20120004244A1 (fr)
EP (1) EP2406219A1 (fr)
JP (1) JP2012520275A (fr)
CN (1) CN102348686A (fr)
AR (1) AR075835A1 (fr)
CA (1) CA2754781A1 (fr)
TW (1) TW201035050A (fr)
WO (1) WO2010103278A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011110824A1 (fr) 2010-03-12 2011-09-15 Biolipox Ab Composés bis aromatiques destinés à être utilisés en tant qu'inhibiteurs de ltc4 synthase
WO2012068406A3 (fr) * 2010-11-18 2012-11-01 Ligand Pharmaceuticals Incorporated Utilisation de mimétiques d'un facteur de croissance hématopoïétique
WO2016177845A1 (fr) 2015-05-06 2016-11-10 Astrazeneca Ab Dérivés d'acide cyclopropane carboxylique et leurs utilisations pharmaceutiques
WO2020234103A1 (fr) 2019-05-21 2020-11-26 Bayer Aktiengesellschaft Identification et utilisation d'inhibiteurs de kras
EP3833352A4 (fr) * 2018-08-10 2022-04-06 University of Central Florida Research Foundation, Inc. Inhibiteurs de transport de polyamine à base de non-polyamine et leur utilisation dans le traitement de cancers humains

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106132928B (zh) 2014-02-28 2019-03-29 橘生药品工业株式会社 苯胺衍生物、含有所述衍生物的药物组合物及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050256102A1 (en) 2004-05-14 2005-11-17 Millennium Pharmaceuticals, Inc. Compounds and methods for inhibiting mitotic progression
WO2006077366A1 (fr) 2005-01-19 2006-07-27 Biolipox Ab Indoles utiles dans le traitement de l'inflammation
WO2008107661A1 (fr) 2007-03-05 2008-09-12 Biolipox Ab Nouveaux composés de méthylène bisphényl utiles dans le traitement d'une inflammation
WO2009030887A2 (fr) 2007-09-04 2009-03-12 Biolipox Ab Composés bis-aromatiques utilisés pour les traitements anti-inflammatoires

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050256102A1 (en) 2004-05-14 2005-11-17 Millennium Pharmaceuticals, Inc. Compounds and methods for inhibiting mitotic progression
WO2006077366A1 (fr) 2005-01-19 2006-07-27 Biolipox Ab Indoles utiles dans le traitement de l'inflammation
WO2008107661A1 (fr) 2007-03-05 2008-09-12 Biolipox Ab Nouveaux composés de méthylène bisphényl utiles dans le traitement d'une inflammation
WO2009030887A2 (fr) 2007-09-04 2009-03-12 Biolipox Ab Composés bis-aromatiques utilisés pour les traitements anti-inflammatoires

Non-Patent Citations (19)

* Cited by examiner, † Cited by third party
Title
"Science of Synthesis", vol. 9-17, 2006, GEORG THIEME VERLAG, article "Hetarenes and Related Ring Systems"
A. R. KATRITZKY; C. W. REES; E. F. V. SCRIVEN: "Comprehensive Heterocyclic Chemistry If", 1996, PERGAMON PRESS
A. R. KATRITZKY; O. METH-COHN; C. W. REES: "Comprehensive Organic Functional Group Transformations", 1995, PERGAMON PRESS
B. M. TROST; I. FLEMING: "Comprehensive Organic Synthesis", 1991, PERGAMON PRESS
BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 14, no. 4, 2004, pages 1023 - 1026
J. A. JOULE; K. MILLS; G. F. SMITH: "Heterocyclic Chemistry", CHAPMAN & HALL
JOURNAL OF ORGANIC CHEMISTRY, vol. 71, no. 9, 2006, pages 3551 - 3558
MOL. PHARMACOL., vol. 41, 1992, pages 873 - 879
ORGANIC AND BIOMOLECULAR CHEMISTRY, vol. 5, no. 3, 2007, pages 494 - 500
ORGANIC LETTERS, vol. 8, no. 26, 2006, pages 5987 - 5990
PHARMAZIE, vol. 61, no. 6, 2006, pages 505 - 510
S.-E. DAHLEN, J. INTERNAL MED., vol. 245, 1999, pages 205
SYNTHESIS, 2006, pages 2618 - 2623
SYNTHESIS, vol. 21, 2006, pages 3547 - 3574
SYNTHETIC COMMUNICATIONS, vol. 36, no. 10, 2006, pages 1405 - 1411
T.W. GREENE; P.G.M. WUTZ: "Protective Groups in Organic Synthesis", 1999, WILEY-INTERSCIENCE
TAKEMIYA ET AL., J. AM. CHEM. SOC., vol. 128, 2006, pages 14800
TETRAHEDRON LETTERS, vol. 47, no. 34, 2006, pages 6063 - 6066
TETRAHEDRON LETTERS, vol. 62, no. 50, 2006, pages 11675 - 11678

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011110824A1 (fr) 2010-03-12 2011-09-15 Biolipox Ab Composés bis aromatiques destinés à être utilisés en tant qu'inhibiteurs de ltc4 synthase
WO2012068406A3 (fr) * 2010-11-18 2012-11-01 Ligand Pharmaceuticals Incorporated Utilisation de mimétiques d'un facteur de croissance hématopoïétique
CN103282034A (zh) * 2010-11-18 2013-09-04 利亘制药公司 造血生长因子模拟物的用途
WO2016177845A1 (fr) 2015-05-06 2016-11-10 Astrazeneca Ab Dérivés d'acide cyclopropane carboxylique et leurs utilisations pharmaceutiques
EP3833352A4 (fr) * 2018-08-10 2022-04-06 University of Central Florida Research Foundation, Inc. Inhibiteurs de transport de polyamine à base de non-polyamine et leur utilisation dans le traitement de cancers humains
WO2020234103A1 (fr) 2019-05-21 2020-11-26 Bayer Aktiengesellschaft Identification et utilisation d'inhibiteurs de kras

Also Published As

Publication number Publication date
US20130035358A1 (en) 2013-02-07
JP2012520275A (ja) 2012-09-06
CA2754781A1 (fr) 2010-09-16
CN102348686A (zh) 2012-02-08
US20120004244A1 (en) 2012-01-05
AR075835A1 (es) 2011-04-27
EP2406219A1 (fr) 2012-01-18
TW201035050A (en) 2010-10-01

Similar Documents

Publication Publication Date Title
WO2009138758A3 (fr) Composés bis-aryles destinés à être utilisés en tant que médicaments
WO2009127822A3 (fr) Composés bis-aryliques destinés à être utilisés en tant que médicaments
MX2010002521A (es) Compuestos bis-aromaticos utiles en el tratamiento de inflamacion.
MX2012015252A (es) Estimuladores de sgc.
MX341531B (es) Derivados de triazol como estimuladores de la guanilato ciclasa soluble gcs.
NZ595572A (en) Inhibitors of pi3 kinase and / or mtor
GEP20125459B (en) Compounds for inhibiting mitotic progression
GEP20125624B (en) Pyridazine derivatives as smo inhibitors
WO2013053983A8 (fr) Inhibiteurs de protéines kinases
IL241791A0 (en) Historical use of 3,1-diphenylprop-2-en-1-one for the treatment of liver disorders
MX2011007750A (es) Composiciones y metodos para inhibicion de la ruta jak.
UA115320C2 (uk) Інгібітори кінази
WO2009016460A8 (fr) Composés pyrazoles
WO2010103278A1 (fr) Composés bi-aromatiques destinés à être utilisés en tant qu'inhibiteurs de ltc4 synthase
WO2009016410A3 (fr) Composés chimiques 831
WO2011058027A3 (fr) Composés de purine n-9-substitués, compositions et procédés d'utilisation
WO2008086122A3 (fr) Dérivés cyclisés en tant qu'inhibiteurs d'eg-5
MX2014006629A (es) Inhibidores de cinasa.
WO2008009924A3 (fr) Indoles utiles dans le traitement de l'inflammation
UA97256C2 (ru) Замещенные пиразолы и триазолы как ингибиторы кбв (кинезин-белок веретена)
MX2010006108A (es) Inhibidores de estearoil-coa-desaturasa.
WO2010102154A3 (fr) Composés acides biaryl oxyacétiques
WO2012054566A3 (fr) Dérivés 6-amido de 4,5a-époxymorphinanes pour traiter une douleur
WO2010072770A3 (fr) Analogues de griséofulvine pour le traitement du cancer par inhibition de l'agrégat centrosomial
PH12012501142A1 (en) Heterocyclic sulfonamide derivatives

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080011041.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10709919

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2754781

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011553512

Country of ref document: JP

Ref document number: 13256003

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2010709919

Country of ref document: EP